In other words, (ruxolitinib + ERBB1/2/4 inhibitor) treatment initially reduces CXCL-1, IL-8, and IL-18 expression that then rebounds in the surviving tumor cells, being over-expressed (Figure 15A) cf in vitro multiplex data in (Figure 3). Here, IL18 is linked to neoplasm.